Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Symbicort in Chronic Obstructive Pulmonary Disease (SYMBOL)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: January 29, 2008
Last updated: January 27, 2011
Last verified: January 2011
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. pneumologists and internists) are asked to document relevant data related to the budesonide/formoterole therapy in patients with COPD.

Chronic Obstructive Pulmonary Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Symbicort in Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Secondary Outcome Measures:
  • to get further insight into the details of the use , dosage scheme and duration of treatment with budesonide /formoterol in this population

Enrollment: 64730
Study Start Date: September 2005
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Patients with COPD treated with budesonide/formoterol


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Inclusion Criteria:

  • Patients with COPD treated with budesonide/formoterol

Exclusion Criteria:

  • limitations; possible risks; warnings; contraindications mentioned in the SPC.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00611520

Sponsors and Collaborators
Study Chair: Kai Richter, MD Medical Department AstraZeneca Germany
  More Information

Responsible Party: Dr Kai Richter, AstraZeneca Germany Identifier: NCT00611520     History of Changes
Other Study ID Numbers: 1312005009
Study First Received: January 29, 2008
Last Updated: January 27, 2011

Keywords provided by AstraZeneca:
treatment of COPD
related to the budesonide/formoterole therapy in patients with COPD.

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Budesonide, Formoterol Fumarate Drug Combination
Anti-Asthmatic Agents
Respiratory System Agents processed this record on May 25, 2017